Special Issue

Advances in the Diagnosis and Antibiotic Treatments of Diabetic Foot Infections

Message from the Guest Editors

This Special Issue aims to highlight recent developments in the diagnosis, treatment, and multidisciplinary management of diabetic foot osteomyelitis (DFO), one of the most severe complications of diabetes. We invite original research articles and reviews from a wide range of disciplines, including infectious diseases, microbiology, radiology, and so on. Suggested topics include the following:

- Imaging techniques and AI applications in DFO diagnosis;
- Microbiological profiling and antimicrobial resistance patterns;
- Biofilm-related challenges and local antibiotic delivery strategies;
- Conservative vs. surgical approaches to managing DFO;
- Emerging treatments and precision medicine in bone infection:
- Guideline-based management and international consensus:
- Interdisciplinary models and patient-centered care;
- Predictive models and outcome-based strategies.

Guest Editors

Prof. Dr. Francisco Javier Álvaro-Afonso

Diabetic Foot Unit, Clínica Universitaria de Podología, Facultad de Enfermería, Fisioterapia y Podología, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense de Madrid, 28040 Madrid, Spain

Prof. Dr. Éric M. Senneville

Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, Tourcoing 59200, Nord-Pas-de-Calais, France

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/241334

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

